Medical Oncologist. がん研有明病院の腫瘍内科医。「人間に基づく医療(HBM)」をモットーに、がん薬物療法や患者さんを支える活動に取り組んでいます。腫瘍内科医育成、新治療開発、がん教育、AYA世代がんのケアに力を入れています。ヨミドクター連載中。著書に「#気持ちがラクになるがんとの向き合い方」。
DIANA-5: randomized trial of an active Mediterranean dietary intervention (vs control) to reduce breast cancer recurrence. 1542 pts randomized. No RFS benefit (HR 0.99).
No evidence to recommend any specific “anti-cancer” diet to pts with breast cancer.
New
#JITC
article: Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
My poster of LIBRA study.
The intervention based on daily ePROs reduced the frequency of diarrhea and improved QOL in patients with advanced breast cancer treated with abemaciclib.
Please come to Board
#305
.
#ASCO24
#BCSM
#LIBRA
#HBM
#ePRO
Interesting analysis of T-DXd related ILD in a large post-marketing cohort of Japanese pts with breast or gastric cancer. Incidence of any-grade ILD was 9.5%; 0.3% had fatal events. Most common pattern: organizing pneumonia (consistent with my experience).
Our paper has just been published:
**Long-term outcomes of JBCRG20 (Neo-peaks) study**
Neoadjuvant T-DM1+pertuzumab and response-guided adjuvant Tx can be a useful option.
Neo-peaks is a randomized phase II study of neoadjuvant Tx for HER2-positive